In contrast, Hsu et al. reported the strong PD-L1 expression in advanced EGFR-mutant NSCLC tumors to be associated with a significantly poorer prognosis in patients that received osimertinib as their first-line EGFR-TKI treatment (Hsu et al., 2022). Here, EGFR is linked to non-small cell lung carcinoma.